Skip to NavigationSkip to content

News

Novartis’ IL-17A inhibitor has chalked up approval from the European Commission (EC) for the treatment of patients between the ages of six and 18...
The EU has reached an agreement with Sanofi for 300 million doses of their COVID-19 vaccine candidate which will allow the trading bloc’s members to...
Two new coronavirus tests are set to be made available throughout England that are significantly faster than most already in use.
The FDA has awarded MorphoSys and Incyte US approval for their Fc-modified cytolytic CD19-targeting monoclonal antibody Monjuvi (tafasitamab-cxix),...
The FDA has approved Epidiolex (cannabidiol) as a treatment for seizures associated with tuberous sclerosis complex (TSC) in patients over one.
The US Government has announced additional funding into Sanofi and GlaxSmithKline’s efforts to develop a recombinant protein-based vaccine to the...
Celltrion's infliximab biosimilar Remsima scores approval for five different indications in Europe, UK Government secures 60 million doses of GSK and...
The financial details of the deal were not revealed, but the delivery of these reserved doses is due to take place in the first half of 2021, at the...
Janssen’s IL-12 and IL-23 inhibitor Stelara (ustekinumab) has had its approved indications expanded by the FDA to include the treatment of skin...
NICE has revealed that a combination of Merck KGaA’s Bavencio (avelumab) and Pfizer’s Inlyta (axitinib) will be made available as a first-line...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches